Please assess the completion status of the following clinical trial:

Trial Title: Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Relapsed or refractory de novo classical Hodgkin lymphoma~* Participant may have failed to achieve a response to, progressed after, or be ineligible for autologous stem cell transplant (auto-SCT)~* Participant may have failed to achieve a response or progressed after treatment with brentuximab vedotin or may be brentuximab vedotin naïve~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Measurable disease~* Adequate organ function~Exclusion criteria:~* Diagnosis of immunosuppression or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication~* Prior monoclonal antibody within 4 weeks prior to study Day 1 or chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks prior to study Day 1~* Prior allogeneic hematopoietic stem cell transplantation~* Known clinically active central nervous system involvement~* Known additional malignancy that is progressing or requires active treatment~* Has a known history of Human Immunodeficiency Virus (HIV)~* Has known active Hepatitis B (HBV) or Hepatitis C (HCV)~* Active autoimmune disease requiring systemic treatment in past 2 years~* Has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle for up to 24 months.
- Cohort 2 (Type: EXPERIMENTAL): Participants with RRcHL who were unable to achieve CR or PR to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months.
- Cohort 3 (Type: EXPERIMENTAL): Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).